Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study
Theresa W Guilbert,Alberto Tolcachier,Alessandro G Fiocchi,Constance Katelaris,Wanda Phipatanakul,Philippe Begin,Inés de Mir,Arman Altincatal,Rebecca Gall,Olivier Ledanois,Amr Radwan,Juby A Jacob-Nara,Yamo Deniz,Paul J Rowe
DOI: https://doi.org/10.2147/jaa.s416292
2024-03-05
Journal of Asthma and Allergy
Abstract:Theresa W Guilbert, 1 Alberto Tolcachier, 2 Alessandro G Fiocchi, 3 Constance H Katelaris, 4, 5 Wanda Phipatanakul, 6, 7 Philippe Begin, 8 Inés de Mir, 9 Arman Altincatal, 10 Rebecca Gall, 11 Olivier Ledanois, 12 Amr Radwan, 11 Juby A Jacob-Nara, 13 Yamo Deniz, 11 Paul J Rowe 13 1 Department of Pediatrics, Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, OH, USA; 2 Center for Allergy and Respiratory Diseases, Buenos Aires, Argentina; 3 Bambino Gesù Children's Hospital IRCCS, Rome, Italy; 4 Department of Medicine, Campbelltown Hospital, Campbelltown, NSW, Australia; 5 Immunology & Allergy Unit, Western Sydney University, Sydney, NSW, Australia; 6 Department of Allergy and Immunology, Boston Children's Hospital, Boston, MA, USA; 7 Department of Pediatrics, Harvard Medical School, Boston, MA, USA; 8 Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, QC, Canada; 9 Pediatric Pulmonary Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; 10 Sanofi, Cambridge, MA, USA; 11 Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 12 Sanofi, Paris, France; 13 Sanofi, Bridgewater, NJ, USA Correspondence: Theresa W Guilbert, Cincinnati Children's Hospital and University of Cincinnati, 3333 Burnet Ave, Cincinnati, OH, 45229, USA, Tel +1 513-636-6771, Email Purpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 inflammation in multiple diseases. This post hoc analysis of the Phase 3 LIBERTY ASTHMA VOYAGE study (NCT02948959) evaluated the efficacy of dupilumab in children aged 6 to 11 years with moderate-to-severe asthma with a type 2 inflammatory phenotype (blood eosinophil count ≥ 150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥ 20 ppb) and a history of 1, 2, or ≥ 3 prior exacerbations. The impact of baseline type 2 biomarker levels on the efficacy of dupilumab in this population was also investigated. Patients and Methods: Patients were stratified by the number of exacerbations in the prior year (1, 2, or ≥ 3) and level of FeNO or blood eosinophil count at baseline. Endpoints included rate of severe exacerbations, percentage of non-exacerbators, and change from baseline in both lung function parameters (pre- and post-bronchodilator [BD] percent predicted forced expiratory volume in 1 s (ppFEV 1 ) and ppFEV 1 /forced vital capacity [FVC] ratio) and Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) score. Results: A total of 350 patients were included in this analysis. Across patients with 1, 2, or ≥ 3 prior exacerbations and different levels of type 2 biomarkers, dupilumab reduced the risk of severe asthma exacerbations vs placebo by 53.0– 96.0% and improved both pre-BD ppFEV 1 and pre-BD FEV 1 /FVC ratio at Week 52. Dupilumab led to significant reductions in ACQ-7-IA scores in all groups of patients by Week 52. Conclusion: In children with uncontrolled, moderate-to-severe asthma with a type 2 phenotype, dupilumab consistently reduced the risk of asthma exacerbations, improved lung function, and reduced ACQ-7-IA scores, regardless of exacerbation history. Keywords: pediatric asthma, type 2 asthma, lung function, asthma control, biologics, anti-interleukin-4 and -13 Graphical Asthma, the most prevalent childhood chronic disease, affects 1 in 12 children in the US, 1 with approximately 5–10% presenting with poorly controlled or uncontrolled severe disease despite receiving standard-of-care treatments at maximally tolerated doses. 2,3 Over half of children with asthma are estimated to have at least one potentially life-threatening severe exacerbation per year. 1 Asthma exacerbations carry significant mortality and economic burden and can predict risk of future exacerbations. 4–6 Thus, there is a considerable need for novel treatments that can reduce asthma exacerbations and improve lung function and asthma control. Type 2 inflammation has been identified as the most common driver of asthma in children, 7 and type 2 inflammatory cytokines such as interleukin (IL)-4 and IL-13 are key in the pathogenesis of asthma. 8 Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for signaling by IL-4 and IL-13, key and central drivers of type 2 diseases such as atopic dermatitis (AD), asthma, allergic rhinitis, and food allergies, which are often associa -Abstract Truncated-
immunology,allergy,respiratory system